The numbers behind the story
Q4 FY 26
March 31, 2026
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended March 31, 2026
Reconciliation of Share Capital as on March 31, 2026
Familiarization Programme
March 24, 2026
Closure of Trading Window
March 20, 2026
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Change in Directors
February 6, 2026
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Update
January 27, 2026
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Update
Q3 FY 26
December 31, 2025
Corporate Governance Report as on December 31, 2025
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended December 31, 2025
Reconciliation of Share Capital as on December 31, 2025
Intimation of Board Meeting
Closure of Trading Window
October 28, 2025
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Update
October 6, 2025
Intimation of change in Email address of MUFG Intime India Private Limited, Registrar and Share Transfer Agent ("MUFG")
October 3, 2025
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Q2 FY 26
September 30, 2025
Corporate Governance Report as on September 30, 2025
Intimation of Board Meeting
Reconciliation of Share Capital as on September 30, 2025
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended September 30, 2025
Closure of Trading Window
September 18, 2025
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Update
September 3, 2025
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Update
August 26, 2025
Intimation on receipt of request for re-lodgement of transfer requests
Advertisement Published in Newspapers regarding Notice to Shareholder (100 DAYS CAMPAIGN - 'SAKSHAM NIVESHAK')
USFDA Establishment Inspection Report ("EIR') - Roha API Plant
Q1 FY 26
June 30, 2025
Intimation of Extension of the exercise period for the options granted and vested under Unichem Employee Stock Option Scheme 2018
Corporate Governance Report as on June 30, 2025
Intimation of Board Meeting
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended June 30, 2025
Reconciliation of Share Capital as on June 30, 2025
Closure of Trading Window
June 21, 2025
USFDA Inspection Report For Roha API Plant
May 14, 2025
USFDA Inspection Report For Pithampur API Plant
April 18, 2025
Intimation of change in contact details of Registrar and Share Transfer Agent ('RTA')
Q4 FY 25
March 31, 2025
Annual Secretarial Compliance Certificate FY2025
Corporate Governance Report as on March 31, 2025
Intimation of Board Meeting
Reconciliation of Share Capital as on March 31, 2025
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended March 31, 2025
Familiarisation Programmes for the financial year 24-25
March 25, 2025
Closure of Trading Window
March 20, 2025
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Capacity Expansion
March 01, 2025
Outcome of Board Meeting
USFDA approval For Company's Pithampur API facility
February 18, 2025
Revision in credit rating
January 27, 2025
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - GST (Goods & Services Tax)
January 24, 2025
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - GST (Goods & Services Tax)
January 03, 2025
Intimation - Change of Name from Link Intime India Private Limited to MUFG Intime India Private Limited
Q3 FY 25
December 31, 2024
Intimation of Board Meeting
Statement of Investor Complaints Pursuant to Regulation 13(3) for the Quarter ended December 31, 2024
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended December 31, 2024
Reconciliation of Share Capital as on December 31, 2024
Corporate Governance Report as on December 31, 2024
December 20, 2024
Intimation of Closure of Trading Window
December 17, 2024
Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 - Resignation of Senior Managerial Personnel ('SMP')
November 13, 2024
Amendment in Fair Disclosure Code
Intimation of Loss of Share Certificate
November 10, 2024
Intimation of Loss of Share Certificate
October 04, 2024
Intimation of Loss of Share Certificate
Q2 FY 25
September 30, 2024
Related Party Transactions for half year ended 30.09.2024
Intimation of Board Meeting
Statement of Investor Complaints Pursuant to Regulation 13(3) for the Quarter ended September 30, 2024
Reconciliation of Share Capital as on September 30, 2024
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended September 30, 2024
Corporate Governance Report as on September 30, 2024
Outcome of Board Meeting
September 23, 2024
Intimation of Board Meeting and Closure of Trading Window
September 10, 2024
USFDA has classified the inspection as Voluntary Action Indicated for Pilerne Bardez, Goa formulation facility
September 01, 2024
Intimation regarding a change in Registered Office w.e.f. 01.09.2024
Advertisement Published in Newspapers regarding registered office shifted w.e.f. 01.09.2024
August 23, 2024
Intimation of Issue of Share Certificate
August 8, 2024
Change in Key Managerial personnel for determining and disclosure of material events
August 5, 2024
Intimation of Loss of Share Certificate
July 1, 2024
Intimation of Loss of Share Certificate
Q1 FY 25
June 30, 2024
Intimation of Board Meeting
Statement of Investor Complaints Pursuant to Regulation 13(3) for the Quarter ended June 30, 2024
Reconciliation of Share Capital as on June 30, 2024
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended June 30, 2024
Corporate Governance Report as on June 30, 2024
Closure of Trading Window
June 27, 2024
Intimation under Regulation 30 of LODR
June 26, 2024
Intimation of loss of Share Certificate
June 17, 2024
Resignation of Internal Auditor
Intimation of loss of Share Certificate
June 12, 2024
Intimation about the Issuance of "Letter of Confirmation in lieu of original share certificate(s) lost by Shareholder
May 31st, 2024
Resignation of KMP
Q4 FY 24
March 31, 2024
Annual Secretarial Compliance Certificate 2024
Related Party Transactions for half year ended 31.03.2024
Intimation of Board Meeting
Reconciliation of Share Capital as on March 31, 2024
Closure of Trading Window
Corporate Governance Report as on March 31, 2024
Certificate under Regulation 40(9) & 40 (10) of the SEBI (LODR) Regulations, 2015 for the financial year ended March 31, 2024
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended March 31, 2024
Compliance Certificate – Regulation 7(3) as on March 31, 2024
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended March 31, 2024
Familiarisation Programmes for the financial year 23-24
March 29, 2024
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Change in Directors
March 27, 2024
Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 - Resignation of Senior Managerial Personnel ('SMP')
January 17, 2024
Intimation about the Issuance of "Letter of Confirmation in lieu of original share certificate(s) lost by Shareholder.
January 11, 2024
ANDA approval from United States Food and Drug Administration (USFDA) for Unichem's Doxazosin Tablets USP, 1 mg, 2 mg, 4 mg and 8 mg.
Q3 FY 24
February 5, 2024
Outcome of the Board Meeting held on February 5, 2024
December 31, 2023
Reconciliation of Share Capital as on December 31, 2023
Intimation of Board Meeting
Statement of Investor Complaints Pursuant to Regulation 13(3) for the quarter ended December 31, 2023
Corporate Governance Report as on December 31, 2023
Compliance Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended December 31, 2023
Closure of Trading Window
December 14, 2023
ICRA – Upgrading of credit rating
December 04, 2023
Sale of Strategic Investment (Optimas) made by the Company
November 24, 2023
Intimation about the loss/misplacement of Share Certificate
October 19, 2023
Intimation about the loss/misplacement of Share Certificate(s)
October 3, 2023
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - GST (Goods & Services Tax)
Q2 FY 24
September 30, 2023
Related Party Transactions for half year ended 30.09.2023
Intimation of Board Meeting
Reconciliation of Share Capital as on September 30, 2023
Corporate Governance Report as on September 30, 2023
Statement of Investor Complaints Pursuant to Regulation 13(3) for the Quarter ended September 30, 2023
Compliance Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended September 30, 2023
Closure of Trading Window
September 21, 2023
Update On open offer
August 29, 2023
ANDA approval from United States Food and Drug Administration (USFDA) for Unichem's Prasugrel Tablets USP, 5 mg and 10 mg.
August 14, 2023
Corrigendum to the Detailed Public Statement (DPS) – Open Offer
August 9, 2023
Outcome of Board Meeting dated August 9, 2023
August 4, 2023
Intimation of Board Meeting and Insider trading window close
August 2, 2023
Update On Sale Of Shares By Promoter To Ipca Laboratories Ltd.
July 28, 2023
Receipt Of CCI Approval For Acquisition Of Shares By Ipca Laboratories Ltd.
July 27, 2023
Intimation about the loss/misplacement of Share Certificate(s)
Q1 FY 24
June 30, 2023
Auditors Certificate on Reconciliation of Share Capital as on June 30, 2023
CG (Corporate Governance) report as on June 30, 2023
Compliance Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended June 30, 2023
Statement of Investor Complaints Pursuant to Regulation 13(3) for the Quarter ended June 30, 2023
Intimation of Board Meeting
Closure of Trading Window
June 26, 2023
Re-appointment of Dr. Prakash A. Mody as the Chairman & Managing Director of the Company
Grant of Employee Stock Options under Unichem Employee Stock Option Scheme 2018
May 15, 2023
Board meeting for Audited results FY 2022-23
May 8, 2023
Intimation about the loss/misplacement of Share Certificate(s)
April 24, 2023
Press Release - April 24, 2023
Public Announcement - April 24, 2023
Disclosure Under Regulation 30 - April 24, 2023
April 19, 2023
Intimation about the loss/misplacement of Share Certificate(s).
Q4 FY 23
March 31, 2023
Annual Secretarial Compliance Certificate 2023
Related Party Transactions for half year ended 31.03.2023
Auditors report on Reconciliation of Share Capital as on March 31, 2023
CG (Corporate Governance) report as on March 31, 2023
Certificate under regulation 40(9) & 40 (10) of the SEBI (LODR) Regulations, 2015 for the financial year ended March 31, 2023
Familiarisation Programmes for the financial year 22-23
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended March 31, 2023
Compliance Certificate – Regulation 7(3) as on March 31, 2023
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended March 31, 2023
Closure of Trading Window
March 20, 2023
Board of Directors - update
Q3 FY 23
December 31, 2022
Intimation of Board Meeting
Reconciliation of Share Capital as on December 31, 2022
Closure of Trading Window
Corporate Governance Report as on December 31, 2022
Compliance Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended December 31, 2022
Statement of Investor Complaints Pursuant to Regulation 13(3) for the Quarter ended December 31, 2022
Q2 FY 23
December 30, 2022
Closure of Trading Window
November 24, 2022
Related Party Transactions for half year ended 30.9.2022
October 14, 2022
ANDA approval from United States Food and Drug Administration (USFDA) for Unichem's Extended Phenytoin Sodium Capsules USP, 100 mg.
September 30, 2022
Intimation of Board Meeting
Reconciliation of Share Capital as on September 30, 2022
Corporate Governance Report as on September 30, 2022
Statement of Investor Complaints Pursuant to Regulation 13(3) for the Quarter ended September 30, 2022
Compliance Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended September 30, 2022
Closure of Trading Window
September 22, 2022
Update on liquidation of strategic investment made by the Company
September 21, 2022
Resignation of Internal Auditor
September 19, 2022
ICRA – assigned credit rating for Rs. 176 crs
August 23, 2022
ANDA approval from United States Food and Drug Administration (USFDA) for for Unichem's Carbamazepine Tablets USP
August 16, 2022
ANDA approval from United States Food and Drug Administration (USFDA) for Unichem's Quetiapine Extended-Release Tablets USP
August 9, 2022
ANDA approval from United States Food and Drug Administration (USFDA) for Unichem's Labetalol Hydrochloride Tablets
Q1 FY 23
June 30, 2022
Intimation of Board Meeting
Reconciliation of Share Capital as on June 30, 2022
Corporate Governance Report as on June 30, 2022
Closure of Trading Window
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended June 30, 2022
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended June 30, 2022
May 30, 2022
Financial Results for the quarter and year ended March 31, 2022 published in the newspapers on May 28 2022.
May 19, 2022
Intimation of Board Meeting
May 10, 2022
Sale of Strategic Investment made by the Company
Q4 FY 22
May 25, 2022
Secretarial compliance report
March 31, 2022
Disclosure of Related Party Transactions on a consolidated basis for half year ended March 31, 2022
Reconciliation of Share Capital as on March 31, 2022
Corporate Governance Report as on March 31, 2022
Certificate Under Regulation 40(9) Of The SEBI (LODR) Regulations, 2015 For The Year Ended March 31, 2022
Closure of Trading Window
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended March 31, 2022
Compliance Certificate – Regulation 7(3) as on March 31, 2022
Familiarisation programme 21-22
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended March 31, 2022
March 16, 2022
ANDA approval from United States Food and Drug Administration (USFDA) for Unichem's Nebivolol Tablets 2.5 mg, 5 mg, 10 mg, and 20 mg.
March 9, 2022
Notice to shareholders of the Company holding shares in physical form for updating of details like PAN, KYC and Nomination etc
February 28, 2022
ANDA approval from United States Food and Drug Administration (USFDA) for Unichem's Divalproex Sodium Extended-Release Tablets USP, 250 mg and 500 mg.
Q3 FY 22
December 31, 2021
Financial Results for the quarter and nine months ended December 31, 2021 published in the newspapers on January 31, 2022.
Reconciliation of Share Capital as on December 31, 2021
Intimation of Board Meeting
Corporate Governance Report as on December 31, 2021.
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended December 31, 2021
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended December 31, 2021
Closure of Trading Window
December 2, 2021
ANDA approval for Aripiprazole Tablets
November 25, 2021
ICRA – assigned credit rating for Rs. 176 crs (increased from Rs. 146 crs to Rs. 176 crs)
Q2 FY 22
September 30, 2021
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended September 30, 2021
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended September 30, 2021
Corporate Governance Report as on September 30, 2021.
Notice of Trading Window Close
Intimation of Board Meeting
Reconciliation of Share Capital as on September 30, 2021
Related Party Transactions
July 31, 2021
Voting results and Scrutinizer's report.
Outcome of 58th Annual General Meeting Proceeding.
Q1 FY 22
June 30, 2021
Intimation of Board Meeting.
Corporate Governance Report as on June 30, 2021.
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended June 30, 2021
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended June 30, 2021
Tentative Approval for ANDA from United States Food and Drug Administration (USFDA) for Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg.
Reconciliation of Share Capital as on June 30, 2021.
Tentative Approval for ANDA from United States Food and Drug Administration (USFDA) for Aripiprazole Tablets, USP, 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg
Notice of Trading Window Close
May 21, 2021
Intimation of Annual General Meeting, Book closure and others
Intimation of Board Meeting to be held on May 29, 2021
Q4 FY 21
March 31, 2021
Disclosure Of Related Party Transactions On Consolidated Basis For Half Year Ended March 31, 2021
Annual Secretarial Compliance Report of the Company for the year ended March 31, 2021
Reconciliation of Share Capital as on March 31, 2021
Corporate Governance Report as on March 31, 2021
Certificate under regulation 40(9) & 40 (10) as on March 31, 2021
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended March 31, 2021
Compliance Certificate – Regulation 7(3) as on March 31, 2021
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended March 31, 2021
Familiarization Programme or Directors for FY 2020 - 2021
Closure of Trading Window
March 4, 2021
ANDA approval from United States Food and Drug Administration (USFDA) for Unichem's Guanfacine Tablets, USP 1 mg and 2 mg.
January 27, 2021
ANDA approval from United States Food and Drug Administration (USFDA) for Unichem's Apremilast Tablets, 10 mg, 20 mg and 30 mg.
ANDA approval from United States Food and Drug Administration (USFDA) for Unichem's Zonisamide Capsules, USP 25 mg, 50 mg and 100 mg.
Q3 FY-21
Reconciliation of Share Capital as on December 31, 2020.
Closure of Trading Window.
Corporate Governance Report as on December 31, 2020.
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended December 31, 2020.
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended December 31, 2020.
January 13, 2021
ANDA approval from USFDA for Unichem's Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg.
January 8, 2021
ICRA – assigned credit rating for Rs. 146 crs (Reduced from Rs. 150 crs) bank facilities
Q2 FY-21
November 28, 2020
ANDA approval from USFDA for Unichem's Atenolol and Chlorthalidone Tablets
September 30, 2020
Disclosure of Related Party Transactions for half year ended September 30, 2020.
Reconciliation of Share Capital as on September 30, 2020.
Intimation of Board Meeting
Certificate under regulation 40(9) & 40 (10) as on September 30, 2020
Corporate Governance Report as on September 30, 2020
Closure of Trading Window
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended September 30, 2020
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended September 30, 2020
Compliance Certificate – Regulation 7(3) as on September 30, 2020
August 29, 2020
Voting results and Scrutinizer's report
Outcome of 57th Annual General Meeting Proceeding
August 6, 2020
ANDA Approval from USFDA for Unichem's Tolterodine Tartrate Tablets
July 23, 2020
Newspaper advertisement for updation of shareholder details
July 22, 2020
ANDA Approval from USFDA for Unichem's Amiodarone Tablets
July 10, 2020
ANDA approval from USFDA for Unichem's Baclofen Tablets
July 07, 2020
ANDA approval from USFDA for Unichem's Cyclobenzaprine Hydrochloride Tablets
Q1 FY-21
June 30, 2020
Reconciliation of Share Capital as on June 30, 2020.
Notice of Board Meeting
Corporate Governance Report as on June 30, 2020
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended June 30, 2020
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended June 30, 2020
Closure of Trading Window
Q4 FY-20
March 31, 2020
Notice of Board Meeting
Reconciliation of Share Capital as on March 31, 2020.
Compliance Certificate – Regulation 7(3) as on March 31, 2020
Certificate under regulation 40(9) & 40 (10) as on March 31, 2020
Corporate Governance Report as on March 31, 2020.
Familiarization Programme 2019-2020
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended March 31, 2020
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended March 31, 2020.
March 30, 2020
Intimation of closure of Trading Window
February 24, 2020
Announcement under Regulation 30 of LODR
January 3, 2020
Credit Rating from ICRA
Initial Intimation Letter
Revised Intimation Letter
Q3 FY-20
December 31, 2019
Notice of Board meeting
Reconciliation of Share Capital as on December 31, 2019.
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended December 31, 2019
Corporate Governance Report as on December 31, 2019.
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended December 31, 2019.
Closure of Trading Window.
November 15, 2019
September 30, 2019 Related Party disclosures for half year ended September 30, 2019.
November 2, 2019
ANDA approval from USFDA for Unichem's Atenolol Tablets USP
Q2 FY-20
September 30, 2019
Related Party disclosures for half year ended September 30, 2019.
Reconciliation of Share Capital as on September 30, 2019.
Notice of Board meeting
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended September 30, 2019.
Corporate Governance Report as on September 30, 2019
Compliance Certificate – Regulation 7(3) as on September 30, 2019
Certificate under regulation 40(9) & 40 (10) as on September 30, 2019
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended September 30, 2019
Closure of Trading Window
September 20, 2019
USFDA approval for Kolhapur plant
September 6, 2019
USFDA approval for Pithampur plant
August 28, 2019
ANDA approval from USFDA for Solifenacin Succinate Tablets, 5 mg and 10 mg.
August 26, 2019
USFDA approval for the Company's Ghaziabad plant
August 13, 2019
ANDA approval from USFDA for Unichem's Tramadol Hydrochloride Tablets
August 12, 2019
ANDA approval from USFDA for Unichem's Chlorthalidone Tablets
August 1, 2019
Appointment of Company Secretary and Compliance Officer
Changes in KMP for dissemination of Material Information
July 31, 2019
Retirement of Company Secretary
July 27, 2019
Outcome of 56TH AGM
Proceedings
Voting results and Scrutinizer's report
July 5, 2019
Setting up of a Wholly Owned Subsidiary in China
Q1 FY-20
June 30, 2019
Reconciliation of Share Capital as on June 30, 2019.
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended June 30, 2019.
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended June 30, 2019.
Corporate Governance Report as on June 30, 2019.
Closure of Trading Window
Notice of Board Meeting
May 3, 2019
Board meeting May 03, 2019
Update on board meeting
Q4 FY-19
March 28, 2019
Outcome of the meeting held on 28.3.2019.
March 27, 2019
Final ANDA Approval from USFDA for Unichem's Tadalafil Tablets 2.5 mg, 5 mg, 10 mg and 20 mg.
March 13, 2019
ANDA approval from USFDA for Unichem's Allopurinol Tablets
March 11, 2019
Ghaziabad Facility is inspected by USFDA
February 26, 2019
Intimation of Appeal against the E.U.
Q3 FY-19
December 31, 2018
Notice of Board meeting published in Newspaper
Notice of Board meeting
Corporate Governance Report as on December 31, 2018
Reconciliation of Share Capital as on December 31, 2018
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended December 31, 2018
December 21, 2018
ANDA approval from USFDA for Unichem's Pramipexole Dihydrochloride Tablets
December 13, 2018
Updation on the EU commission Litigation
December 11, 2018
Tentative ANDA Approval from USFDA for, Unichem’s Tadalafil Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg.
November 14, 2018
Postal Ballot Newspaper Advertisement
November 2, 2018
Strategic Investment In Optimus Drugs Private Limited and Optrix Laboratories Private Limited
October 22, 2018
EIR for Unichem’s API manufacturing facilities at Pithampur and Roha
Q2 FY-19
September 30, 2018
Notice of Board Meeting
Corporate Governance Report as on September 30, 2018
Reconciliation of Share Capital as on September 30, 2018
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended September 30, 2018
Compliance Certificate – Regulation 7(3) as on September 30, 2018
Certificate under regulation 40(9) & 40 (10) as on September 30, 2018
September 24, 2018
Credit Rating from ICRA
September 3, 2018
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
August 7, 2018
Grant of Stock Options under the Unichem Employee Stock Option Scheme 2018
July 28, 2018 – 55th AGM
Outcome of 55th AGM – Scrutinizer’s Report
Outcome of 55TH AGM – Results under Regulation 44 of the Listing Regulations
Proceedings of 55th AGM
NOTICE OF 55thANNUAL GENERAL MEETING, REMOTE E-VOTING AND BOOK CLOSURE
July 4, 2018
Receipt of ANDA approval from USFDA for Unichem's Montelukast Chewable Tablets, 4 mg and 5 mg.
July 3, 2018
Financial Statements of Subsidiaries for the financial year ended 2017-2018
Niche Genercis Limited
Unichem Farmaceutica Do Brazil Ltda
Unichem Laboratories Limited- Ireland
Unichem Pharmaceutical (USA), Inc.
Unichem SA (Propreitary) Limited
Q1 FY-19
June 30, 2018
Notice of Board Meeting
Corporate Governance Report as on June 30, 2018
Reconciliation of Share Capital as on June 30, 2018
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter
June 20, 2018
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Unichem has entered into a settlement agreement with Eli Lilly & Company and ICOS Corporation to resolve their patent litigation in the United States District Court for the District of New Jersey regarding Unichem's Abbreviated New Drug Application for generic tadalafil (Cialis®). Under the settlement agreement, Unichem expects to launch its generic tadalafil product in the United States on or not before March 26, 2019 under certain circumstances.
June 6, 2018
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Unichem's formulation manufacturing facility at Ghaziabad has received an Establishment Inspection Report (EIR) from USFDA indicating closure of inspection. The inspection was conducted by FDA in April 2018.